BioCatalyst

Remibrutinib, Teriflunomide — catalyst calendar

2 verified catalyst event(s) referencing Remibrutinib, Teriflunomide, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-07-23
in 1mo
ESTIMATED
 READOUT
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants Wi
Phase 3 · Relapsing Multiple Sclerosis
 NVS NOVARTIS AG Remibrutinib, Teriflunomide ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-07-23
in 1mo
ESTIMATED
 READOUT
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants Wi
Phase 3 · Relapsing Multiple Sclerosis
 NVS NOVARTIS AG Remibrutinib, Teriflunomide ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.